Statement: Gemcitabine is not used in the primary trial, and used only in cohort 2 of the secondary trial.
Primary_evidence: INTERVENTION 1:    Experimental   cyclophosphamide: chemotherapy   doxorubicin hydrochloride: chemotherapy   adjuvant therapy: chemotherapy   radiation therapy: chemotherapy
Secondary_evidence: INTERVENTION 1:    Arm A: Nab-Paclitaxel + Gemcitabine   Participants received nab-Paclitaxel 125 mg/m^2 on Days 1 and 8 by intravenous (IV) administration followed by gemcitabine 1000 mg/m^2 on Days 1 and 8 by IV administration of each 21-day treatment cycle. Participants continued treatment until progressive disease (PD), unacceptable toxicity, required palliative radiotherapy or surgical intervention of lesion(s), withdrawal from study treatment, withdrawal of study consent, participant refusal or the investigator felt it was no longer in the best interest of the participant to continue on treatment INTERVENTION 2:    Arm B: Nab-Paclitaxel + Carboplatin   Participants received nab-Paclitaxel 125 mg/m^2 on Days 1 and 8 by IV administration followed by carboplatin area under the curve 2 (AUC 2) on Days 1 and 8 in each 21-day treatment cycle. Participants continued treatment until progressive disease (PD), unacceptable toxicity, required palliative radiotherapy or surgical intervention of lesion(s), withdrawal from study treatment, withdrawal of study consent, participant refusal or the investigator felt it was no longer in the best interest of the participant to continue on treatment.